MedTrace Logo

Safety and Tolerability of GX-P1 in Healthy Male Volunteers

NCT04298749 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2021-07-27

No results posted yet for this study

Summary

This study is a single-center, double-blind, placebo-controlled, phase I study with healthy male volunteers receiving ascending single dose of GX-P1

Conditions

Interventions

DRUG

GX-P1 or Placebo (dose level 1)

GX-P1 dose level 1 or placebo

DRUG

GX-P1 or Placebo (dose level 2)

GX-P1 dose level 2 or placebo

DRUG

GX-P1 or Placebo (dose level 3)

GX-P1 dose level 3 or placebo

Sponsors & Collaborators

  • Genexine, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-11
Primary Completion
2021-06-07
Completion
2021-06-07

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04298749 on ClinicalTrials.gov